Brokerages Set Stryker Co. (NYSE:SYK) PT at $421.90

Shares of Stryker Co. (NYSE:SYK) have been assigned a consensus recommendation of “Moderate Buy” from the twenty brokerages that are presently covering the firm, MarketBeat reports. Four research analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company. The average 1-year price objective among analysts that have issued a report on the stock in the last year is $421.90.

A number of research analysts have weighed in on SYK shares. JMP Securities reaffirmed a “market perform” rating on shares of Stryker in a report on Tuesday, February 18th. JPMorgan Chase & Co. raised their target price on Stryker from $420.00 to $445.00 and gave the company an “overweight” rating in a research report on Wednesday, January 29th. Needham & Company LLC reaffirmed a “buy” rating and issued a $442.00 price target on shares of Stryker in a report on Friday, March 21st. Wells Fargo & Company increased their price target on Stryker from $427.00 to $435.00 and gave the stock an “overweight” rating in a research report on Wednesday, January 29th. Finally, Barclays boosted their price objective on Stryker from $418.00 to $443.00 and gave the company an “overweight” rating in a research report on Monday, February 10th.

Stryker Stock Down 4.4 %

Shares of SYK opened at $347.04 on Tuesday. The stock’s 50-day moving average price is $376.39 and its 200-day moving average price is $373.61. The company has a quick ratio of 1.32, a current ratio of 1.95 and a debt-to-equity ratio of 0.59. The company has a market capitalization of $132.46 billion, a price-to-earnings ratio of 44.72, a PEG ratio of 2.93 and a beta of 0.93. Stryker has a 52 week low of $314.93 and a 52 week high of $406.19.

Stryker (NYSE:SYK) last issued its quarterly earnings data on Tuesday, January 28th. The medical technology company reported $4.01 EPS for the quarter, topping analysts’ consensus estimates of $3.87 by $0.14. Stryker had a net margin of 13.25% and a return on equity of 23.58%. During the same quarter in the previous year, the business posted $3.46 EPS. On average, sell-side analysts predict that Stryker will post 13.47 EPS for the current year.

Stryker Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 30th. Investors of record on Monday, March 31st will be paid a dividend of $0.84 per share. The ex-dividend date of this dividend is Monday, March 31st. This represents a $3.36 annualized dividend and a yield of 0.97%. Stryker’s dividend payout ratio is presently 43.30%.

Insiders Place Their Bets

In other news, Director Allan C. Golston sold 2,458 shares of the stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $383.07, for a total transaction of $941,586.06. Following the completion of the transaction, the director now directly owns 14,895 shares in the company, valued at approximately $5,705,827.65. This represents a 14.16 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Ronda E. Stryker sold 201,392 shares of the business’s stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $392.24, for a total transaction of $78,993,998.08. Following the completion of the sale, the director now owns 3,642,075 shares in the company, valued at approximately $1,428,567,498. This trade represents a 5.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 5.90% of the company’s stock.

Institutional Investors Weigh In On Stryker

A number of institutional investors have recently made changes to their positions in SYK. Kohmann Bosshard Financial Services LLC acquired a new stake in Stryker in the 4th quarter valued at approximately $25,000. Capital A Wealth Management LLC purchased a new position in shares of Stryker during the fourth quarter worth $26,000. Dunhill Financial LLC grew its stake in shares of Stryker by 94.9% in the third quarter. Dunhill Financial LLC now owns 76 shares of the medical technology company’s stock valued at $27,000 after buying an additional 37 shares in the last quarter. Rakuten Securities Inc. raised its holdings in shares of Stryker by 618.2% in the 4th quarter. Rakuten Securities Inc. now owns 79 shares of the medical technology company’s stock valued at $28,000 after buying an additional 68 shares during the period. Finally, Centricity Wealth Management LLC acquired a new position in Stryker during the 4th quarter worth about $30,000. 77.09% of the stock is currently owned by institutional investors and hedge funds.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.